Kévin Premat1, Eimad Shotar2, Robert Burns2, Natalia Shor2, Gauthier Eloy3, Évelyne Cormier2, Mehdi Drir4, Laetitia Morardet5, Stéphanie Lenck2, Nader Sourour2, Jacques Chiras2, Didier Dormont2, Raphaël Bonaccorsi3, Frédéric Clarençon2. 1. Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, Department of Neuroradiology, F75013, Paris, France. kevin.premat@aphp.fr. 2. Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, Department of Neuroradiology, F75013, Paris, France. 3. Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, Department of Orthopaedic Surgery, F75013, Paris, France. 4. Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, Department of Anaesthesiology, F75013, Paris, France. 5. Sorbonne University, AP-HP, Pitié Salpêtrière - Charles Foix Hospital, Department of Oncology, F75013, Paris, France.
Abstract
OBJECTIVES: Preoperative embolization of hypervascular spinal metastases (HSM) is efficient to reduce perioperative bleeding. However, intra-arterial digital subtraction angiography (IA-DSA) must confirm the hypervascular nature and rule out spinal cord arterial feeders. This study aimed to evaluate the reliability and accuracy of time-resolved contrast-enhanced magnetic resonance angiography (TR-CE-MRA) in assessing HSM prior to embolization. METHODS: All consecutive patients referred for preoperative embolization of an HSM were prospectively included. TR-CE-MRA sequences and selective IA-DSA were performed prior to embolization. Two readers independently reviewed imaging data to grade tumor vascularity (using a 3-grade and a dichotomized "yes vs no" scale) and identify the arterial supply of the spinal cord. Interobserver and intermodality agreements were estimated using kappa statistics. RESULTS: Thirty patients included between 2016 and 2019 were assessed for 55 levels. Interobserver agreement was moderate (κ = 0.52; 95% CI [0.09-0.81]) for TR-CE-MRA. Intermodality agreement between TR-CE-MRA and IA-DSA was good (κ = 0.74; 95% CI [0.37-1.00]). TR-CE-MRA had a sensitivity of 97.9%, a specificity of 71.4%, a positive predictive value of 95.9%, a negative predictive value of 83.3%, and an overall accuracy of 94.6%, for differentiating hypervascular from non-hypervascular SM. The arterial supply of the spine was assessable in 2/30 (6.7%) cases with no interobserver agreement (κ < 0). CONCLUSIONS: TR-CE-MRA can reliably differentiate hypervascular from non-hypervascular SM and thereby avoid futile IA-DSAs. However, TR-CE-MRA was not able to evaluate the vascular supply of the spinal cord at the target levels, thus limiting its scope as a pretherapeutic assessment tool. KEY POINTS: • TR-CE-MRA aids in distinguishing hypervascular from non-hypervascular spinal metastases. • TR-CE-MRA could avoid one-quarter of patients referred for HSM embolization to undergo futile conventional angiography. • TR-CE-MRA's spatial resolution is insufficient to replace IA-DSA in the pretherapeutic assessment of the spinal cord vascular anatomy.
OBJECTIVES: Preoperative embolization of hypervascular spinal metastases (HSM) is efficient to reduce perioperative bleeding. However, intra-arterial digital subtraction angiography (IA-DSA) must confirm the hypervascular nature and rule out spinal cord arterial feeders. This study aimed to evaluate the reliability and accuracy of time-resolved contrast-enhanced magnetic resonance angiography (TR-CE-MRA) in assessing HSM prior to embolization. METHODS: All consecutive patients referred for preoperative embolization of an HSM were prospectively included. TR-CE-MRA sequences and selective IA-DSA were performed prior to embolization. Two readers independently reviewed imaging data to grade tumor vascularity (using a 3-grade and a dichotomized "yes vs no" scale) and identify the arterial supply of the spinal cord. Interobserver and intermodality agreements were estimated using kappa statistics. RESULTS: Thirty patients included between 2016 and 2019 were assessed for 55 levels. Interobserver agreement was moderate (κ = 0.52; 95% CI [0.09-0.81]) for TR-CE-MRA. Intermodality agreement between TR-CE-MRA and IA-DSA was good (κ = 0.74; 95% CI [0.37-1.00]). TR-CE-MRA had a sensitivity of 97.9%, a specificity of 71.4%, a positive predictive value of 95.9%, a negative predictive value of 83.3%, and an overall accuracy of 94.6%, for differentiating hypervascular from non-hypervascular SM. The arterial supply of the spine was assessable in 2/30 (6.7%) cases with no interobserver agreement (κ < 0). CONCLUSIONS: TR-CE-MRA can reliably differentiate hypervascular from non-hypervascular SM and thereby avoid futile IA-DSAs. However, TR-CE-MRA was not able to evaluate the vascular supply of the spinal cord at the target levels, thus limiting its scope as a pretherapeutic assessment tool. KEY POINTS: • TR-CE-MRA aids in distinguishing hypervascular from non-hypervascular spinal metastases. • TR-CE-MRA could avoid one-quarter of patients referred for HSM embolization to undergo futile conventional angiography. • TR-CE-MRA's spatial resolution is insufficient to replace IA-DSA in the pretherapeutic assessment of the spinal cord vascular anatomy.
Entities:
Keywords:
Magnetic resonance angiography; Reproducibility of results; Sensitivity and Specificity; Spine
Authors: S Nishimura; T Hirai; Y Shigematsu; M Kitajima; M Morioka; Y Kai; R Minoda; H Uetani; R Murakami; Y Yamashita Journal: AJNR Am J Neuroradiol Date: 2011-11-24 Impact factor: 3.825
Authors: N R Khadem; S Karimi; K K Peck; Y Yamada; E Lis; J Lyo; M Bilsky; H A Vargas; A I Holodny Journal: AJNR Am J Neuroradiol Date: 2012-05-03 Impact factor: 3.825
Authors: Daniel E Spratt; Whitney H Beeler; Fabio Y de Moraes; Laurence D Rhines; Joseph J Gemmete; Neeraj Chaudhary; David B Shultz; Sean R Smith; Alejandro Berlin; Max Dahele; Ben J Slotman; Kelly C Younge; Mark Bilsky; Paul Park; Nicholas J Szerlip Journal: Lancet Oncol Date: 2017-12 Impact factor: 41.316
Authors: Shuling Li; Yi Peng; Eric D Weinhandl; Anne H Blaes; Karynsa Cetin; Victoria M Chia; Scott Stryker; Joseph J Pinzone; John F Acquavella; Thomas J Arneson Journal: Clin Epidemiol Date: 2012-04-10 Impact factor: 4.790